Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.

Autor: Prendergast EN; University of California Los Angeles, Division of Gynecologic Oncology, Los Angeles, CA, USA., Holman LL; Stephenson Oklahoma Cancer Center, Division of Gynecologic Oncology, Oklahoma City, OK, USA., Liu AY; University of California Los Angeles, Division of Gynecologic Oncology, Los Angeles, CA, USA., Lai TS; University of California Los Angeles, Division of Gynecologic Oncology, Los Angeles, CA, USA., Campos MP; University of California Los Angeles, Division of Hematologic Oncology, Los Angeles, CA, USA., Fahey JN; University of California Los Angeles, Division of Gynecologic Oncology, Los Angeles, CA, USA., Wang X; University of California Los Angeles, Division of General Medicine and Health Services Research, USA., Abdelaal N; Stephenson Oklahoma Cancer Center, Division of Gynecologic Oncology, Oklahoma City, OK, USA., Rao JY; University of California Los Angeles, Department of Pathology, Los Angeles, CA, USA., Elvin JA; Foundation Medicine, Inc., 150 Second Street, Cambridge, MA, USA., Moore KM; Stephenson Oklahoma Cancer Center, Division of Gynecologic Oncology, Oklahoma City, OK, USA., Konecny GE; University of California Los Angeles, Division of Gynecologic Oncology, Los Angeles, CA, USA; University of California Los Angeles, Division of Hematologic Oncology, Los Angeles, CA, USA. Electronic address: gkonecny@mednet.ucla.edu., Cohen JG; University of California Los Angeles, Division of Gynecologic Oncology, Los Angeles, CA, USA.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2019 Sep; Vol. 154 (3), pp. 461-466. Date of Electronic Publication: 2019 Jun 27.